Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.
Also called NCT01237873
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 150 participants
- Sponsor
- Registry
-
NCT01237873
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01237873. Allocation not applicable; no masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2012-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension
- Condition
- Essential Hypertension
- Intervention (Drug)
- Ali/Amlo 150/2.5 mg
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01237873- Content hash
d5baf9a3cfa4734960555c43cbcc8110b92c3a1e05d4b5644f1c5219c4b8c3e8